VGF Changes during the Estrous Cycle: A Novel Endocrine Role for TLQP Peptides?

Barbara Noli, Carla Brancia, Filomena D’Amato, Gian-Luca Ferri*, Cristina Cocco*

Department of Biomedical Sciences, University of Cagliari, Monserrato (Cagliari), Italy

Abstract

Although the VGF derived peptide TLQP-21 stimulates gonadotropin-releasing hormone (GnRH) and gonadotropin secretion, available data on VGF peptides and reproduction are limited. We used antibodies specific for the two ends of the VGF precursor, and for two VGF derived peptides namely TLQP and PGH, to be used in immunohistochemistry and enzyme-linked immunosorbent assay complemented with gel chromatography. In cycling female rats, VGF C-/N-terminus and PGH peptide antibodies selectively labelled neurones containing either GnRH, or kisspeptin (VGF N-terminus only), pituitary gonadotrophs and lactotrophs, or oocytes (PGH peptides only). Conversely, TLQP peptides were restricted to somatostatin neurones, gonadotrophs, and ovarian granulosa, interstitial and theca cells. TLQP levels were highest, especially in plasma and ovary, with several molecular forms shown in chromatography including one compatible with TLQP-21. Among the cycle phases, TLQP levels were higher during metestrus-diestrus in median eminence and pituitary, while increased in the ovary and decreased in plasma during proestrus. VGF N- and C-terminus peptides also showed modulations over the estrous cycle, in median eminence, pituitary and plasma, while PGH peptides did not. In ovariectomised rats, plasmatic TLQP peptide levels showed distinct reduction suggestive of a major origin from the ovary, while the estrogen-progesterone treatment modulated VGF C-terminus and TLQP peptides in the hypothalamus-pituitary complex. In in vitro hypothalamic, TLQP-21 stimulated release of growth hormone releasing hormone but not of somatostatin. In conclusion, various VGF peptides may regulate the hypothalamus-pituitary complex via specific neuroendocrine mechanisms while TLQP peptides may act at further, multiple levels via endocrine mechanisms involving the ovary.

Introduction

The VGF gene product, and/or its derived peptides, appear to be involved in reproduction since vgf null mice were sexually immature and almost completely infertile [1]. The 66 kDa VGF precursor [1–6] is composed of 617 or 615 amino acid residues (in rat or human, respectively), and gives rise to several low molecular weight VGF peptides which are abundant in multiple brain regions, peripheral neurones, and certain endocrine and neuroendocrine cell populations [7–13]. Despite their abundance and wide distribution, limited data are available on their role and function/s. Among the VGF peptides with proven biological activity are included TLQP-21 [14], TLQP-62 [15] and the peptides called NERPs [16]. TLQP-21 was shown to act on various mechanisms, including the regulation of energy balance [14], inflammatory and neuropathic pain [17,18], chronic stress [19], and gastric motility and emptying [20]. With respect to reproduction, induction of VGF mRNA was reported in the pituitary immediately after the estrus, in parallel with a clear-cut decrease in certain VGF peptides, as well as changes in their localisation in gonadotrophs and lactotrophs [21]. A distinct seasonal modulation in cell-type-specific processing of the VGF precursor was revealed in the anterior pituitary of female sheep [22], while significant upregulation of VGF mRNA was found related to reproductive maturation in baboon ovary [23]. More recently, TLQP-21 was shown to exert a number of actions on the rat reproductive axis [24,25]. Central administration of TLQP-21 in pubertal and adult male rats induced gonadotropin secretion via release of gonadotropin-releasing hormone (GnRH), and stimulated testosterone secretion in vitro in pre-pubertal animals [24]. In female pre-pubertal rats, TLQP-21 induced in vitro secretion of luteinising hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, with no detectable effect on GnRH release from the hypothalamus [25]. On the same rats, upon i.p. injection of the same peptide at high doses, serum LH showed a moderate increase, while after central administration of TLQP-21 in adults animals, the LH response was dependent on the stage of the reproductive cycle [25]. On the whole, TLQP-21 would so far appear to affect female reproduction by stimulating pituitary LH release. We produced antisera selective for the C- and N-terminal portions of the VGF precursor, and for two cleaved peptides “TLQP” and “PGH” (named from the corresponding four N-terminal, and three C-terminal amino-acids, respectively, immediately adjacent to their respective sites of cleavage from the
Materials and Methods

Animals and tissue samples

Sprague Dawley adult female rats (from Charles River, Italy, 200–250 g body weight) were kept at 22°C (12:12-h light/dark cycle, lights on 7 am–7 pm), 3 to 4 rats per cage, with food and water ad libitum. All animals were killed at the same time of day (approximately 10 am), with a diethyl ether overdose. Group 1 (“cycling rats”) included females showing regular 4 days estrous cycles (vaginal smears were taken daily at 8.30–9.30 during about 2 consecutive cycles, on average). Rats were killed at the age of 12–14 weeks, at proestrus, estrus, diestrus, or metestrus (n = 12 per each cycle phase). Group 2 rats (“ovariectomy + estrogen/progesterone treatment”, n = 8) were bilaterally ovariectomised at 3–4 weeks’ age, hence received intraperitoneal beta-estradiol (200 μg/200 ul, 2 days before sacrifice) and progesterone (500 μg/200 ul, on the day of sacrifice). Group 3 rats (“ovariectomy controls”, n = 7) were as for group 2, but received the corresponding solvent only (seed oil). Rats from groups 2 and 3 were sacrificed in parallel, 4 hours after the progesterone/oil injection. All experimental protocols were approved by the Ethical Committee at the University of Cagliari, and were performed in accordance with the guidelines for the care and use of animals approved by the American Physiological Society, the EEC Council Directive of 24 November 1986 (86/609) and the relevant Italian legislation. For ELISA experiments, the brain, hypophysis and ovaries were extracted from each rat as follows: group 1, n = 8 per phase; group 2, n = 5; group 3, n = 4. For group 1, the median eminence was dissected (under a stereomicroscope) from the remainder of the hypothalamus, and the two were separately extracted. The whole hypothalamus, inclusive of the median eminence, was taken from rats of groups 2 and 3. Blood (approximately 5 ml) was drawn at sacrifice (hence for cycling rats at the morning of each cycle phase as above mentioned) from the left heart of every animal, collected in an EDTA (1.78 mg/ml) containing tube, and rapidly centrifuged (3,000 × g, 10–15 minutes), hence plasma was stored frozen. Tissues were extracted in ice-cold phosphate buffered saline (PBS, 0.01 mol/l PO₄, pH 7.2–7.4, 0.15 mol/l NaCl: 10 ml/g tissue) containing protease inhibitor cocktail (P8340, Sigma-Aldrich, Schnelldorf, Germany), homogenized for 3 minutes using an ultra Turrax (Ika-Werke, Staufen, Germany), hence tubes were heated in a vigorously boiling water bath for 10 minutes, and centrifuged (3,000 xg, 10 minutes). Supernatants were stored frozen until use (−20°C or lower). For IHC, rats (group 1, n = 4; groups 2 and 3, n = 3 each) were transcardially perfused with 4% paraformaldehyde (in 0.2 mol/l PO₄ buffer, pH = 7.2), hence brain, pituitary and ovary were dissected out, and rinsed overnight in PBS containing 7% sucrose. Samples were oriented in aluminium foil moulds with cryoembedding media [26], snap-frozen and stored in a liquid nitrogen tank (vapour phase). Sections (5–7 um) were obtained using a cold-blade cryomicrotome [27] (Microm HM-560, Walldorf, Germany), and collected on poly-L-lysine treated slides.

Antibodies

The antibodies used are summarized in Table 1. VGF peptides used for immunizations (Fig. 1) encompassed: (i) the rat VGF C-terminal nonapeptide; (ii) the N-terminal decapetide of the rat VGF precursor (VGF24-33, upon cleavage of the rat VGF1-23 signal peptide); (iii) the N-terminal decapetide of rat TLQP peptides (rat VGF556-565), and: (iv) the C-terminal nonapeptide of PGH peptides (rat VGF422-430). These were conjugated with bovine thyroglobulin or keyhole limpet haemocyanin, via either an additional N-terminal D-tyrosine residue (for VGF C-terminus and PGH), or an additional C-terminal cysteine (for VGF N-terminus and TLQP), as previously described (Tables 1–2). Hormone and hypothalamic factor antibodies (Table 1) showed negligible (<0.5%) cross reactivity with other pituitary hormones [21,22].

Characterization of VGF antibodies

Specificity was addressed in parallel via immunohistochemistry and ELISA. In the former, labeling with each VGF antibody was prevented by pre-absorbed with the relevant peptide (up to 500 nmol/ml). At the C-terminus of VGF, the rat sequence shows a single amino acid difference versus human VGF (Table 2). Both the human nonapetide and other peptide missing the last three C-terminal amino acids (HVLL) showed negligible reactivity in ELISA (Table 2), while in IHC the rat VGF C-terminus antibody showed: (i) low reactivity on human tissues; (ii) clear-cut no-colocalisation of VGF C-terminus and HVLL immunostaining [28]. On such basis, the latter antibody is considered to recognise a short intact sequence at the extreme C-terminus of rat VGF. Species differences are shown in the VGF N-terminal decapetide (Table 2), with very low reactivity of mouse and human forms in ELISA. Hence, antibody reactivity would depend on a comparatively long portion of the immunogen sequence. Cleaved peptides with an exposed TLQP or PGH sequence (i.e. with such sequence present at their N-terminus, and C-terminus, respectively) can be formed via proteolysis at the adjacent cleavage sequence: Arg355+Pro354+Arg353, for TLQP peptides [12], and: Arg431+Arg432, for PGH peptides. Synthetic peptides similar to immunogens, with the addition of one extra Arginine in the location of their respective cleavage sequence (“Arginine-extended”, see Table 2), were used to gain insight into the potential cross-reactivity of antibodies with native extended peptides (these may include the whole VGF precursor, or any peptides cleaved from VGF and including the TLQP or PGH sequence internally). In ELISA, the coating of specific peptide antigen onto the wells, together with high antibody dilutions, results in selection of the antibodies taking part in the reaction, hence in a major increase in specificity for cleaved peptides. Furthermore, most native peptides will be extended by many more than the one (Arginine) residue we tested, thus favouring low cross-reactivity.

Immunostaining

Sections were incubated overnight in a hummid chamber, with antibodies diluted in PBS containing 30 ml/l of normal donkey serum, 30 ml/l of normal rat serum, and 0.02 g/l NaN₃. Double and triple immunofluorescence experiments were carried out mixing a VGF antibody with one hormone or hypothalamic factor antibody (Table 1) obtained in a different donor species. The relevant species-specific secondary antibody/ies (all from donkey, affinity purified IgG preparations absorbed with serum proteins from multiple species, conjugated with either Cy3, Cy2 or AMCA: Jackson Immunoresearch Laboratories, West Grove, PA) were used to reveal the sites of primary antibody binding. Slides were coveredslipped with PBS-glycerol, observed and photographed using....
BX41 and BX51 fluorescence microscopes (Olympus, Milan, Italy) equipped with Fuji S2 and S3 Pro digital cameras (Fujifilm, Milan, Italy). Further to absorption controls (see above), routine controls included substitution of each antibody, in turn, with PBS, the use of pre-immune or non-immune sera, and the testing of each secondary antibody with their respective non-relevant primary antibodies.

**Table 1.** Antisera and antibodies used in the study.

| Antigen | Specie | Ref. | Dilutions | use |
|---------|--------|------|-----------|-----|
| **VGF peptides** | | | | |
| C-t. | Rabbit | Feni et al. 1995 | 1:250 K/1:3 K | E/I |
| TLQP | G. Pig | Brancia et al. 2005 | 1:60 K/1:1000 | E/I |
| PGH | Rabbit | D’Amato et al. 2008 | 1:60 K/1:1000 | E/I |
| N-t. | G. Pig | Cocco et al. 2010 | 1:400 K/1:800 | E/I |
| **Hormones** | | | | |
| FSH | Mouse | Berger et al. 1990 | 1:500 | I |
| GH | Monkey | AF Parlow | 1:800 | I |
| LH | Sheep | Biomol/Enzo | 1:600 | I |
| PRL | Mouse | Berger et al. 1990 | 1:600 | I |
| GHRH | Rabbit | Phoenix | 1:16000 | E |
| GHRH | GHRH Rabbit | Phoenix | 1:6000 | E |
| **h. factors** | | | | |
| GnRH | Mouse | Stermb | 1:2000 | I |
| SRIF | Rabbit | Abcam | 1:20 K/1:600 | E/I |
| Kiss | Rabbit | Millipore | 1:800 | I |

C-t.: VGF C-terminus; N-t.: VGF N-terminus; FSH: follicle-stimulating hormone; GH: growth hormone; LH: luteinising hormone; PRL: prolactin; h. factor: hypothalamic factor, GHRH: growth hormone-releasing hormone; GnRH: gonadotrophin-releasing hormone; SRIF: somatostatin, Kissp: kisspeptin; Ref: references; E: ELISA; I: immunohistochemistry.

doi:10.1371/journal.pone.0108456.t001
**Table 2. ELISA characterization.**

| Peptide | Sequence | IC₅₀ | CV1 | CV2 | % cross-reactivity |
|---------|---------|------|-----|-----|-------------------|
| rVGF₆₀₉–₆₁₇ | --dY-IEHV LLHRP | | | | |
| C-t | \(\text{rVGF}_{607-615}\) | IEHV LLRRP | 0.02 | 2–3 | 4 | <0.01 |
| | \(\text{rVGF}_{603-612}\) | LEN YIEHV LL | | | | <0.01 |
| | \(\text{rVGF}_{556-565}\) | TLQPP ASSRR--C | | | | |
| | \(\text{rVGF}_{556-564}\) | TLQPP ASSRR | | | | |
| TLQP | \(\text{rVGF}_{556-567}\) | TLQPP ASSRR R | 1.1 | 3–5 | 6 | 122 |
| | \(\text{rVGF}_{556-576}\) | TLQPP ASSRR RHFHH ALPPA R | | | | 183 |
| | \(\text{rVGF}_{556-564}^\text{R₁}\) | R-TLQPP ASSR | | | | 3.5 |
| | \(\text{rVGF}_{422-430}\) | --dY-RSQEE APGH | | | | |
| | \(\text{rVGF}_{419-427}\) | RSQEE APGH-R | 0.3 | 4–6 | 6–8 | <0.015 |
| | \(\text{rVGF}_{419-428}^\text{R₄}\) | RSQEE TPGH-R | 3.5 | | | |
| | \(\text{rVGF}_{23-30}\) | APPGR PEAPQ | 10 | 3–7 | 5–8 | <0.001 |
| | \(\text{rVGF}_{24-31}\) | APPGR SDVYP--C-- | | | | 100 |
| | \(\text{mVGF}_{24-31}\) | APPGR PDVFP | | | | <0.001 |

Sequence differences versus rat VGF are underlined; IC₅₀: dose producing 50% inhibition (pmol per well); CV1 and CV2: intra and inter assay variation, respectively; C-t and N-t: VGF C-terminus and N-terminus, respectively; ² “immunogen”: peptide used for conjugation to carrier protein and immunizations; used for plate coating and assay standards; R₁: Arg-extended: with addition of Arginine residue at the peptide N- or C-terminus, respectively; R₄ additional Arginine residue from adjacent cleavage site; “dY” and “C”: additional d-Tyrosine, or Cysteine residue used for conjugation; r: rat, h: human, m: mouse.

doi:10.1371/journal.pone.0108456.t002

**ELISA**

ELISA VGF assays were carried out as described previously [28–29]. Briefly, multiwell plates were coated with either the relevant VGF peptide (Table 2), or synthetic GHRH (Bachem, Bubendorf, Switzerland, 120 pmol/ml), as appropriate, and blocked with PBS containing 9% normal donkey serum and 0.05% NaN₃ (2 h). Primary incubations were carried out with a mixture of the relevant primary antibody (in PBS containing 9% normal donkey serum, 20 nmol/L aprotinin, 1 mg/ml EDTA and 0.05% NaN₃), and either samples (diluted 1:5 to 1:40), or serial dilutions of the relevant standard peptide, or the relevant peptides to be tested for characterization purposes (Table 2). Detection was carried out with the relevant secondary antibody (affinity purified donkey IgG, absorbed with serum proteins from multiple species, biotin conjugated: 1 h, from: Jackson), streptavidin-peroxidase conjugate (Biospa, Milan, Italy: 30 min), and tetramethylbenzidine substrate (TMB X-tra, Kem-En-Tec Diagnostics, Taastrup, Denmark). Optical density was measured at 450 nm using a multilabel plate reader (Chameleon, Hidex, Turku, Finland). For all VGF peptides studied, overall recovery of loaded immunoreactivity ranged between 80% and 100%.

**Chromatography**

Extracts (2 ml) were individually loaded onto a Sephadex G-50S column (Sigma; 2 cm × 1 m), equilibrated with 50 mM ammonium bicarbonate and eluted with the same buffer. A molecular weight (MW) marker kit (MWGF70: Sigma) was used for column calibration. Fractions (3 ml) were reduced in volume with a Vacufuge Concentrator (Eppendorf, Milan, Italy) and assessed by ELISA. For all VGF peptides studied, overall recovery of loaded immunoreactivity ranged between 80% and 100%.

**In vitro experiments**

In view of the specific localisation of TLQP peptides in median eminence somatostatin-containing terminals, we hypothesized a possible action onto secretion of somatostatin and its GHRH neurone targets. Adult male rats (Sprague Dowley, 300–350 g body weight, n = 12) were killed by decapitation, and their brain was rapidly dissected out. Each hypothalamus (from optic chiasm to mammilary bodies, about 2 mm wide) was incubated in Dulbecco’s modified Eagle’s medium (DMEM, with 4.5 g/L glucose, without glutamine) in a 95% O₂ and 5% CO₂ atmosphere, at 37°C, as previously described [24]. After 30 min, the medium was removed and substituted with fresh medium with/without TLQP-21 (10⁻⁶ mol/L; n = 6 and 6 hypothalami). After a further 45 minutes incubation, culture media were collected, heat treated in a boiling water bath for 30 min, and stored frozen pending somatostatin and GHRH assays.

**Statistical analysis**

Data were expressed as mean ± SEM throughout. Statistical analyses were carried out by one-way ANOVA, followed by t-test.
as appropriate (StatistiXL software, www.statistixl.com), and a \( P < 0.05 \) was considered statistically significant.

Results

VGF peptide immunolocalisation

Immunoreactive VGF peptides were revealed in multiple areas of the reproductive axis as hypothalamus, including the preoptic area (POA) and median eminence, as well as in hypothalamic and ovarian cells (Fig. 2 and 3). Experiments focused on the POA showed PGH peptide immunoreactivity in the majority of GnRH axons and terminals (Fig. 2, A and B), with weak labeling of some GnRH containing perikarya (not shown). The same applied to VGF C-and N-terminus antibodies, with the latter additionally labeling almost all kisspeptin containing fibres (Fig. 2C and D). In the median eminence, TLQP peptides were brightly immunostained (Fig. 2, E), confined to somatostatin containing axons and terminals (Fig. 2, F). VGF C- and N-terminus peptides were far more widely distributed throughout the external and internal median eminence, including axons and terminals containing GnRH (Fig. 2, G and H), or kisspeptin (VGF N-terminus only, not shown). PGH peptides showed a discrete localisation, in the lateral portion of the median eminence, virtually completely colocalised with GnRH (Fig. 2, I and J). The above distribution profiles of VGF peptides in the POA and median eminence remained broadly similar over the estrous cycle (not shown). In the anterior pituitary (Fig. 2, K-Q), all VGF antisera labelled large numbers of endocrine cells. The majority (80–90%) proved to be LH containing gonadotrophs (Fig. 2, K-N and O, P: TLQP and PGH peptides, respectively). A small proportion (about 10–20%) of VGF C- or N-terminus, or PGH immunoreactive cells (Fig. 2, O, Q) were prolactin containing lactotropes. In the morning following estrus, immunostaining of gonadotropes (especially with VGF C-and N-terminus and TLQP antibodies) was reduced, with an increase of visible labeling in a fraction of lactotropes, as shown previously [21] (Fig. 2, K, L versus M, N: diestrus versus estrus, respectively).

In the ovary (Fig. 3), TLQP peptide immunoreactivity was revealed in the granulosa (Fig. 3A) as well as in the theca and interstitial cells (Fig 3B). Conversely, PGH peptide/s were restricted to oocytes (Fig. 3, C), and VGF C- and N-terminus peptide labeling was scanty. In ovariectomised rats, most hypertrophic pituitary gonadotropes showed VGF peptide immunoreactivity, with intense to moderate labeling intensity, as reported previously [21].

Changes in cycling females

As with any other quantitative method based on the use of antibodies, the numerical values of peptide concentrations measured in ELISA ought to be considered with caution, pending sequencing of the relevant native peptide/s, hence use of proper standards.

Nonetheless, TLQP peptides appeared to be most abundant in all areas we studied, as well as in plasma (Fig. 4), with lowest levels for VGF C-and N-terminus peptides in ovary and plasma. Along the estrous cycle, TLQP levels were higher during metestrus in median eminence and during metestrus and diestrus in pituitary. The same peptides were more abundant in ovary and lower in plasma during proestrus, compared to the other phases. VGF C- and N-terminus peptides, too, increased during metestrus and/or diestrus in median eminence and pituitary, as well as in plasma. PGH peptides failed to show significant modulation.

Ovariectomy and hormonal treatment

In the absence of hormonal treatment, upon ovariectomy TLQP peptides were greatly reduced in plasma (roughly 20% of average levels in cycling females: Figs. 4, 5). The other VGF peptides studied were also decreased, to very low levels. As measured in the “whole hypothalamus”, post-ovariectomy TLQP and PGH peptides were roughly comparable to cycling females, while VGF N- and C-terminus peptides were reduced (Figs. 4, 5). In the pituitary, most VGF peptides studied were distinctly increased, except for VGF C-terminus containing ones. Upon estrogen-progesterone treatment, a differential response was shown for TLQP and VGF C-terminus peptides, both further increasing in the pituitary, while in hypothalamus TLQP increased, and VGF C-terminus peptides were reduced (Fig. 5).

In plasma, all VGF peptides studied showed a tendency to increase after hormonal treatment, with significant differences for VGF N-terminus peptides only.

Molecular heterogeneity

To resolve small to medium MW peptides we resorted to gel chromatography, with detection by ELISA in view of its enhanced selectivity for internally cleaved peptides (see above). Three major peaks were shown for TLQP peptides (Fig. 6, left: a, b, c), closely matching the elution positions shown previously for TLQP-62, TLQP-30 and TLQP-21 [30]. Such forms were found in all tissues studied and in plasma, with a lower TLQP-21 peak in the ovary. Higher MW forms were seen, at approximately 10–12 kDa and in the void volume, or in the region overlapping the void volume in plasma (Fig. 6, left). VGF C-terminus immunoreactivity was revealed in the void volume (Fig. 6, mid-left: d), compatible with VGF precursor, and in a major broad peak in the approximately 10–15 kDa range (ibidem: e, f). A lower peak (ibidem: g, h) appeared to relate to the TLQP “a” peak described above. The same peptides were mostly seen as low MW fragments in the ovary, while migrating as large forms in plasma (Fig. 6, mid-left).

The VGF N-terminus assay also showed abundant reactivity in the large MW fractions from plasma (Fig. 6, mid-right: refer “g” to bottom panel), with lower levels at varied MW in tissue extracts. In the hypothalamus, the N-terminal VGF24–63 peptide [31] may take part in the lower MW portion (Fig. 6, mid-right: h) of a broad, approximately 3–10 kDa interval of immunoreactive fractions. PGH peptides were revealed as different MW forms, especially in the hypothalamus (Fig. 6, right). The largest MW forms eluting in the void volume were low in tissues and abundant in plasma (ibidem: i). Interestingly, an intermediate MW peak (ibidem: m, roughly 30–50 kDa) might correspond to PGH peptide/s encompassing the whole portion between the PGH sequence and either of the known cleaved rat peptides: VGF180–209, or VGF24–36 [31,32], see (Fig. 1). The low MW peak shown (ibidem: n) fits well with the reported PGH8 peptide [33], running between the PGH sequence and the immediately preceding cleavage site (rat VGF: Lys^{421}Ar{422}).

In vitro experiments

A single dose of TLQP-21 was tested, comparable to the one shown to induce release of GnRH from male rat hypothalamus [24]. Upon addition of TLQP-21 to the culture medium, somatostatin release into the medium showed a non-significant tendency to decrease (Fig. 7, left panel). Conversely, GHRH release was significantly enhanced (approximately 50%, Fig. 7, right panel).
Figure 2. VGF peptide localisation in hypothalamus and pituitary. In the preoptic area (A–D), PGH peptides (A) were immunostained within almost all neuronal terminals containing GnRH (B) conversely, VGF N-terminus peptides (C) were also revealed in most kisspeptin neuronal terminals (D): A, C: Cy3 red labeling; B, D: Cy2 green labeling. In the median eminence (E–J), TLQP peptides (E) were selectively found in almost all somatostatin neuronal terminals and axons (F). Conversely, VGF C-terminus (G) and PGH (I) antibodies labeled GnRH neurone terminals (H and J, respectively): E, G, I: Cy3 red labeling; F, H, J: Cy2 green labeling. In the pituitary (K–Q), the number of cells positive with both TLQP (K, M) and LH (L, N) antibodies was higher in diestrous (K, L) than in estrous phase (M, N). Conversely, the PGH peptides (O) were found in a large number of LH cells (P) and in a few PRL cells (Q, colocalised cells are identified by the arrows). Scale bars: A–B, E–Q: 100 um, C–D: 50 um.
doi:10.1371/journal.pone.0108456.g002

Figure 3. VGF peptide localisation in Ovary. TLQP peptide immunoreactivity was found in the granulosa (A) as well as in the theca and interstitial cells (B), while PGH peptides were restricted to the oocyte (C). All VGF staining: Cy3 red labeling. Scale bar: 50 um.
doi:10.1371/journal.pone.0108456.g003
Discussion

Our study demonstrated the presence of several peptides derived from the VGF precursor, with selective differential profiles at all levels of the hypothalamic-pituitary-ovarian axis. A striking modulation in peptide tissue levels including plasma was shown across the estrous cycle, implicating VGF peptides in events and mechanisms relevant to reproduction.

In view of the proposed role of VGF as multifunctional precursor of bioactive peptides our study was focused on end products of the VGF precursor, rather than on the primary VGF gene product itself. The primary sequence of VGF shows at least ten putative cleavage sites, in the form of two or more basic amino acid residues, highly conserved across species. Recently, further fragments including bioactive VGF peptides have been shown to derive from cleavage at single basic amino acids [16,34,35]. In view of the lower proteomic complexity of the cerebro-spinal fluid (CSF), the precise chemical nature of VGF derived end products has so far been mostly studied in such body fluid [36] with the addition of neuro-endocrine cells lines [33]. An array of VGF peptides and fragments have been revealed, with striking changes in neurodegenerative and other disease conditions [37–40]. Certain VGF peptides proved to be released in vivo in the brain upon neuronal depolarization [31] while an interactomic investigation revealed selective domains of VGF, including the TLQP-21 region, as likely binding partners for the amyloid precursor protein [41]. Similarly, two peptides derived from non-overlapping regions of the VGF precursor were reported in the protein-bound and unbound fractions, respectively, from CSF [42]. In the present study, TLQP-antibodies showed several chromatography peaks fitting well with known VGF peptides, such as TLQP-21, -30 and -62 [30]. Products derived from the C-terminal domain of VGF have been studied in some detail [11,12] and the major molecular form/s we found in hypothalamus and pituitary may represent so-called VGF18 and 20 (such denomination refers to migration in western blot, not to MW). In connection with the TLQP-62 peak shown here with the relevant N-terminal antibody (“TLQP rat 556–565” antibody), a lower amount of reactivity was revealed in chromatography with the corresponding C-terminus antibody. The very high selectivity of such antibody that we found for the unmodified C-terminal sequence suggests that TLQP-62 peptide/s may partly undergo limited processing at their C-terminal end. Other peptides derived from the C-terminal domain of the VGF precursor may have gone undetected in our study, due to a degree of processing or change at their C-terminus. At the other extreme...
of VGF, a fully N-terminal 40 amino acid peptide has been proved to be released upon neuronal depolarization [31]. Such peptide may take part in a broad region of immunoreactivity we found in the hypothalamus and probably elsewhere. A small PGH peptide ("PGH8"), corresponding to a sequence running from the C-terminal peptide sequence we used to raise antibodies ("PGH rat 422–430" antibody), to the immediately preceding putative cleavage site (Lys-Arg, rat VGF 421–422, "R" preceding the "PGH rat 422–430") was demonstrated in mouse neuroblastoma cells [33]. While several intermediate MW PGH peptides are difficult to interpret, one may speculate that the broad immunoreactive peak close to the void volume that we found in gel

Figure 5. VGF peptide levels in ovariectomised (OVX) rats. Levels of TLQP, C-/N-terminus and PGH peptides were measured in the hypothalamus (including median eminence), pituitary, and plasma of OVX rats with and without oestradiol-progesterone (EP) treatment: OVX+EP and OVX, respectively. OVX+EP rats revealed an increase for TLQP peptides in hypothalamus and pituitary as well as changes for C-terminal peptides. In plasma, after EP treatment an increase was revealed for N-terminal peptides only. The PGH peptides did not reveal any change. Pmol/g: picomoles per grams; pmol/ml: picomoles per millilitres; *p<0.05, **p<0.005.
doi:10.1371/journal.pone.0108456.g005
chromatography could include putative, large VGF fragments running from the PGH sequence to a region close to the N-terminus of VGF. In plasma, we revealed certain VGF peptides possibly including TLQP-21, TLQP-30 and TLQP-62, however, in general, a large MW peak was prominent with all VGF assays. This may indicate that one or more VGF peptides travel in the circulation bound to plasma proteins. In fact, many polypeptides are known to bind to major plasma proteins, and/or to their selective transporter/s. Concerning to our study, one ought to notice that tissue extracts underwent at least some treatment steps (e.g. heat treatment) which would reduce molecular interactions of VGF peptides with other molecules, while plasma samples was

Figure 6. Sephadex chromatography. Three major peaks were shown for TLQP peptides (left: a, b, c), corresponding to TLQP-62, TLQP-30 and TLQP-21 and found in all tissue extracts. Higher MW forms were seen, at approximately 10–12 kDa and in the void volume, or in the region overlapping the void volume in plasma. VGF C-terminus immunoreactivity was revealed in the void volume (mid-left: d), compatible with VGF precursor, and in a major broad peak in the approximately 10–15 kDa range (ibidem: e), while a lower peak (ibidem: f) appeared related to the TLQP “a” peak described above. The same peptides were mostly seen as low MW fragments in the ovary, while migrating as large forms in plasma (mid-left). The VGF N-terminus assay revealed abundant reactivity in the large MW fractions from plasma (mid-right; refer “g” to bottom panel), with lower levels at varied MW in the other tissue extracts. PGH peptides were revealed as different MW forms, especially in the hypothalamus while the largest MW forms eluting in the void volume were abundant in plasma (ibidem: i). Molecular weight markers are shown with the corresponding arrows.

Pmol/f: picomoles/fraction; f: fraction.
doi:10.1371/journal.pone.0108456.g006

Figure 7. TLQP-21 in in vitro experiments. TLQP-21 included in the medium of hypothalamic samples up-regulates the secretion of growth-hormone-releasing hormone (GHRH). Contr.: control medium analysed by ELISA without the addition of TLQP-21 versus the medium including the peptide (TLQP column).
doi:10.1371/journal.pone.0108456.g007
neither extracted, nor treated before assays. While examples of the binding of VGF peptides to other components are provided above, the possibility that at least some of the VGF-immunoreactive large MW forms found in plasma may represent actual VGF precursor cannot be excluded.

On this context, the selective differential MW profiles of the VGF peptides were found in parallel with a striking modulation in their tissue levels across the estrous cycle.

With respect to the TLQP peptides, as mentioned, they were found within median eminence somatostatin neurones, gonadotrophic and ovary cells with high tissue levels especially in ovary and plasma. In the blood, their low levels in ovariectomised rats showed the ovary as a major source of circulating TLQP peptides. During the cycle, we showed an increase in pituitary TLQP levels on metestrus–diestrus. This is according to the increase in LH secretion obtained after TLQP-21 iv administration in adult female rats on the same diestrous phase [25]. Moreover, we reported here that, on proestrous, the TLQP ovary levels were augmented, but during the following phases (including the diestrous), the same ovary reduced its TLQP peptide content that concurrently augmented in blood. The possible involvement of TLQP peptides in endocrine mechanisms related to reproduction is suggested also by the reported increase in LH secretion after concurrently augmented in blood. The possible involvement of diestrus), the same ovary reduced its TLQP peptide content that augmented, but during the following phases (including the ovary) that contain their potential receptors. This autocrine/paracrine role could involve the regulation of LH secretion, related to the LH production at the pituitary [25] but not at the gonadal level. As to the potential TLQP receptors, the same C3a/C3AR1 molecules that have been found to modulate the pituitary hormonal activity [43] have been reported to be the targets of the TLQP-21 in the hamster ovary cell lines [44]. Hence, the same ovary that secretes TLQP peptides into the blood could be regulated by its own derived peptides, or alternatively the circulating TLQP peptides reacting to the ovary receptors could originate, at least in part, from the hypophysis. This is suggested by our finding in estrous phase, where a marked reduction in TLQP pituitary levels (according to a minor number of immunolabeled cells) was found in parallel with a TLQP plasmatic increase.

Moreover, we cannot exclude the possibility that TLQP peptides could also act through a paracrine and/or autocrine way, in view of their presence in the same organs (pituitary and ovary) that contain their potential receptors. This autocrine/paracrine role could involve the regulation of LH secretion, according to the mentioned augment in TLQP pituitary levels on the same phase in which the LH secretion was found to increase [25]. Indeed, an autocrine role have been already demonstrated for other VGF peptides as NERPs that being present within the vasopressin cells, regulated the same vasopressin production [16,34]. On the other end, our results showed also that TLQP peptides in the pituitary and hypothalamus could be up-regulated by the oestradiol/progesterone.

These hormones regulate also somatostatin [45], and being TLQP peptides present in such neurones, it is possible that steroid hormones could modulate both TLQP and somatostatin by the same mechanisms. Regarding the role of TLQP peptides in the median eminence, in view of their close relation to somatostatin seen also in pancreas [46] and stomach [30], we tried to elucidate a possible bioactivity of TLQP-21 on somatostatin and on its GHRH neurone targets. We found that TLQP-21 up-regulated the GHRH production suggesting that such peptide could act promoting the growth at the hypothalamic level. When adult male mice were chronically treated (by icv injection) with TLQP-21, physiological, molecular and behavioral parameters related to the GH axis were investigated, however, TLQP-21 did not modulate the GH axis [47]. One could hypothesize that TLQP-21 may regulate GHRH through somatostatin neurones selectively at the median eminence level, instead when the same peptide is injected, only a little part could reach the median eminence. Further experiments are needed to ascertain the precise role of TLQP-21 on the growth mechanisms and the possible connections with the cycle. Regarding the other VGF peptides, also C- and N-terminus peptides changed in the hypothalamus, pituitary and plasma. However, for these peptides is more difficult to hypothesize mechanisms of action in view of the rare information regarding their involvement on reproduction. It could be only suggested that these peptides could have a neuroendocrine and/or endocrine activity on the estrous cycle, and their presence into kisspeptin neurones is intriguing because of the importance of this hormone in reproductive mechanisms [48,49]. Furthermore, also the presence of PGH peptides in gonadotrophs, GnRH neurones, plasma and especially within the oocyte, needs more investigation.

In conclusion, various VGF peptides may regulate the hypothalamic-pituitary complex via specific neuroendocrine mechanisms. In particular, for TLQP peptides we may hypothesize different possible interacting ways of action on the reproduction including endocrine pathways largely involving the ovary as well as paracrine/autocrine mechanisms at both the pituitary and ovary levels.

In addition, we also found evidence for an involvement of TLQP-21 on neuroendocrine mechanisms acting on promoting growth at the median eminence level.

Supporting Information

Data S1 TLQP and C-terminus assay results. For each assay, data referring to picomoles per gram or milliliter revealed by ELISA for each single animal case in each tissue tested through the 4 cycle phases. (TIFF)

Data S2 N-terminus and PGH assay results. For each assay, data referring to picomoles per gram or milliliter revealed by ELISA for each single animal case in each tissue tested through the 4 cycle phases. (TIFF)

Data S3 TLQP, C-terminus, N-terminus and PGH assay results. For each assay, data referring to picomoles per gram and milliliter revealed by ELISA for each single animal case in each tissue tested through the 4 cycle phases. (TIFF)

Data S4 Somatostatin and GHRH assay results. For each assay, data referring to picomoles per gram and milliliter revealed by ELISA for each single animal case in each tissue tested using ovariectomised rats without any hormonal treatment (OVX) and treated with estrogen-progesterone (OVX + EP). (TIFF)
Acknowledgments

We thank C. Mostallino at the National Research Council, Institute of Neuroscience, Cagliari, for rat stabulation. Dr. Peter Berger, National Institute of Diabetes and Digestive and Kidney Diseases and Dr. A.F. Parlow for providing antibodies.

Author Contributions

GLF raised antisera. Conceived and designed the experiments: BN CC. Performed the experiments: BN FD CB. Analyzed the data: BN CC GB. Contributed reagents/materials/analysis tools: GLF. Contributed to the writing of the manuscript: CC GLF.

References

1. Hahn S, Minno TM, Wu TJ, Wisor JP, Priest CA, et al. (1999) Targeted deletion of the vgf gene indicates that the encoded secretory peptide precursor plays a novel role in the regulation of energy balance. Neuron 23: 337–348.
2. Levi A, Eladry JD, Paterson BM (1983) Molecular cloning of a gene sequence regulated by nerve growth factor. Science 229: 393–5.
3. Salton SR, Fischberg DJ, Dong KW (1991) Structure of the gene encoding VGF, a nervous system-specific mRNA that is rapidly and selectively induced by nerve growth factor in PC12 cells. Mol Cell Biol 11(5): 2335–2349.
4. Snyder SE, Pintar JE, Hair RL, Wray GA, Alberts SC (2012) Changes in gene associated protein in rat adenohypophysis: sex differences and changes during the estrous cycle. Behav Brain Res 229(2): 333–5.
5. Babbitt CC, Tung J, Wray GA, Alberts SC (2012) Changes in gene associated protein in rat adenohypophysis: sex differences and changes during the estrous cycle. Behav Brain Res 229(2): 333–5.
6. Van den Pol AN, Decavel C, Levi A, Paterson B (1989) Hypothalamic expression of a novel gene product, VGF: immunochemical analysis. J Neurosci 9: 4122–4137.
7. Van den Pol AN, Bina K, Decavel C, Ghosh P (1994) VGF expression in the human brain. J Comp Neurol 347: 435–469.
8. Levi A, Ferri GL, Watson E, Possenti R, Salton SR (2004) Processing, distribution, and function of VGF, a neuronal and endocrine peptide precursor. Crit Rev Neurobiol 21: 517–33.
9. Possetti R, Rinaldi AM, Ferri GL, Borboni P, Trani E, et al. (1999) Expression, processing, and secretion of the neuroendocrine VGF peptides by INS-1 cells. Endocrinology 140: 3727–3735.
10. Salton SR, Cocco C, Melis GV, Aste L, et al. (2000) VGF: a novel role for this neuronal and neuroendocrine polypeptide in the regulation of energy balance. Front Neuroendocrinol 21: 199–219.
11. Bartolomucci A, La Corte G, Possenti R, Locatelli V, Rigamonti AE, et al. (2002) Isolation and characterization of VGF peptides in rat brain. Role of PC1/3 and PC2 in the maturation of VGF precursor. J Neurochem 81: 565–574.
12. Canu N, Possenti R, Rinaldi AM, Trani E, Levi A (1997) Molecular cloning and characterization of the human VGF promoter region. J Neurochem 68: 1390–1399.
13. Bartolomucci A, La Corte G, Possenti R, Locatelli V, Rigamonti AE, et al. (2006) TLQP-21, a VGF-derived peptide, increases energy expenditure and prevents the early phase of diet-induced obesity. Proc Natl Acad Sci U S A 103(39): 14534–14539.
14. Rozzi U, Zetterberg H, Podust VN, Gottfries J, Li S, et al. (2005) Identification of a receptor for neuropeptide VGF and its role in proteolytic processing, and secretion of the neuroendocrine VGF peptides by INS-1 cells. Endocrinology 140: 3727–3735.
15. Trani E, Giorgi A, Canu N, Amadoro G, Rinaldi AM, et al. (2002) Isolation and characterization of VGF peptides in rat brain. Role of PC1/3 and PC2 in the maturation of VGF precursor. J Neurochem 81: 565–574.
16. Canu N, Possenti R, Rinaldi AM, Trani E, Levi A (1997) Molecular cloning and characterization of the human VGF promoter region. J Neurochem 68: 1390–1399.
17. Rizzi R, Bartolomucci A, Moles A, D’Amato FR, Sacerdote P, et al. (2008) The VGF-derived peptide TLQP-21: in vivo and in vitro studies in male rats. J Endocrinol 207: 329–341.
18. Rizzu P, Zetterberg H, Podust VN, Gottfries J, Li S, et al. (2005) Identification of CSF biomarkers for frontaltemporal dementia using SELDI-TOF. Experimental Neurol 196: 273–281.
19. Busse S, Bernstein HG, Buse M, Bielau H, Bruch R, et al. (2012) Reduced density of hypothalamic VGF- and immuno-reactive neurones in schizophrenia: a potential link to impaired growth factor signaling and energy homeostasis. Eur Arch Psychiatry Clin Neurosci 262(5): 365–74.
20. Asato T, Koizumi S, Takagi A, Hatori T, Kuwabara K, et al. (2011) Identification of a novel biomarker candidate, a 4/4kDa peptide fragment from a neurosecretory protein VGF precursor, by proteomic analysis of cerebrospinal fluid from children with acute encephalopathy using SELDI-TOF-MS. Neurology 111: 101.
21. Bui Y, Markham K, Chen F, Verweersker R, Watts J, et al. (2005) The in vivo brain interaction of the amyloid precursor protein. Mol Cell Proteomics 4(1): 15–34.
22. Wijte D, McDonnell LA, Balog CI, Bossers K, Deelder AM, et al. (2012) A novel peptidomics approach to detect markers of Alzheimer’s disease in cerebrospinal fluid. Methods 56(4): 500–7.
23. Francis K, Lewis RM, Akatsu H, Moon PN, Cain SA (2003) Complement C3a receptors in the pituitary gland: a novel pathway by which an innate immune molecule releases hormones involved in the control of inflammation. FASEB J 17(13): 2996–8.
24. Hannelefouche S, Beck V, Leighton-Davies J, Beibl M, Roma G, et al. (2013) Identification of the C3alpha receptor (C3AR1) as the target of the VGF-derived peptide TLQP-21 in rodent cells. J Biol Chem 288(30): 27434–27443.
25. Van Vliet I, Van de Heijning BJ, Van der Biek EM (2008) Somatosstatin in the rat periventricular nucleus: sex differences and effect of gonadal steroids. Exp Brain Res 188(4): 483–491.
26. Cocco C, Brancia C, Pirsig I, D’Amato F, Noli B, et al. (2007) VGF metabolic related gene: distribution of its derived peptides in mammalian pancreatic islets. J Histochim Cytochem 55: 619–620.
47. Bartolomacci A, Rigamonti AE, Balcarelli I, Torsello A, Locatelli V, et al. (2007) Chronic intracerebroventricular TLQP-21 delivery does not modulate the GH/IGF-1-axis and muscle strength in mice. Growth Horm IGF Res 17(4): 342–5.

48. Navarro VM, Castellano JM, Fernández-Fernández R, Tovar S, Roa J, et al. (2005) Effects of KiSS-1 peptide, the natural ligand of GPR54, on follicle-stimulating hormone secretion in the rat. Endocrinology 146(4): 1689–1697.

49. Adachi S, Yamada S, Takatsu Y, Matsui H, Kinoshita M, et al. (2007) Involvement of anteroventral periventricular metatin/kisspeptin neurons in estrogen positive feedback action on luteinizing hormone release in female rats. J Reprod Dev 53(2): 367–78.